Australian Gonococcal Surveillance Programme, 1 July to 30 September 2024
DOI:
https://doi.org/10.33321/cdi.2025.49.018Keywords:
antimicrobial resistance, Neisseria gonorrhoeae, gonococcal infection, disease surveillanceAbstract
The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin and tetracycline are included in the AGSP Annual Report.
Downloads
References
Northern Territory Government Department of Health (NT Health) Centre for Disease Control. Penicillinase-producing Neisseria gonorrhoeae (PPNG) and treatment recommendations for gonorrhoea. Darwin: NT Health; 11 March 2024. [Accessed on July 11 2024.] Available from: https://health.nt.gov.au/__data/assets/pdf_file/0008/1356146/health-alert-ppng-240311.pdf.
World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/44863.
Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A et al. Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill. 2022;27(46):2200803. doi: https://doi.org/10.2807%2F1560-7917.ES.2022.27.46.2200803.
van Hal SJ, Sherry N, Coombs G, Mowlaboccus, S, Whiley DM, Lahra MM. Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone. Lancet Infect Dis. 2024;24(9):e547–8. doi: https://doi.org/10.1016/S1473-3099(24)00486-9.
Lahra MM, Van Hal S, Hogan TR. Australian Gonococcal Surveillance Programme Annual Report, 2022. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.45.
van Hal SJ, Whiley DM, Le T, Ray S, Kundu RL, Kerr E et al. Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype. J Antimicrob Chemother. 2023;78(9):2203–2208. doi: https://doi.org/10.1093/jac/dkad221.
Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364. doi: https://doi.org/10.1186/s12879-015-1029-2.
Ong JJ, Bourne C, Dean JA, Ryder N, Cornelisse VJ, Murray S et al. Australian sexually transmitted infection (STI) management guidelines for use in primary care, 2022 update. Sexual Health. 2023;20(1):1-8. doi: https://doi.org/10.1071/SH22134.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
